98 citations
,
November 1999 in “Dermatology Online Journal” IGF-1 can boost hair growth by promoting cell growth and preventing cell death.
70 citations
,
March 2010 in “The Journal of Steroid Biochemistry and Molecular Biology” Blocking a specific enzyme might help treat obesity and diabetes, but more research is needed to ensure it's safe.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
September 2025 in “Obstetrics and gynecology.” Myoinositol effectively manages PCOS with fewer side effects than metformin.
11 citations
,
December 2018 in “Bone” Removing a methyl group from the ITGAV gene speeds up bone formation in a specific type of bone disease model.
38 citations
,
May 1971 in “Clinical genetics” A specific metabolite, not a receptor protein, triggers the production of certain kidney enzymes, but this process is disrupted in mice with a mutation causing testicular feminization.
8 citations
,
July 2019 in “Pure and Applied Chemistry” Some natural compounds from Iris plants can block enzymes related to certain disorders, with a few affecting both targeted enzymes.
222 citations
,
August 2014 in “Cell Metabolism” Mitochondrial Complex I reduces inflammation and increases bone breakdown by affecting certain immune cells.
January 2017 in “Seoul National University Open Repository (Seoul National University)” AIMP1 can boost hair growth by increasing stem cell activity.
2 citations
,
May 2012 in “Indian drugs” Finasteride, a hair loss treatment, works better and is more stable when delivered through specially prepared gels, leading to increased hair growth.
8 citations
,
April 1991 in “European journal of endocrinology” 3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.
The document concludes that scientists created various steroids with different properties, including a more effective semi-synthetic vitamin D.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
27 citations
,
January 2018 in “Drug Delivery” GC10/DOX hydrogel shows promise as an effective thyroid cancer treatment.
6 citations
,
March 1996 in “Journal of Investigative Dermatology”
7 citations
,
April 2019 in “The Journal of Steroid Biochemistry and Molecular Biology” 11α-Hydroxyprogesterone is changed into different substances by certain enzymes and may play a role in prostate cancer.
May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
April 2025 in “Molecular Biology Reports” DNMT1 may help treat hypospadias by improving cell function and preventing unwanted cell changes.
May 2025 in “Experimental Dermatology” A new genetic tool improves the study of hair growth and potential hair disorder treatments.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” 3 citations
,
October 1994 in “Journal of Dermatological Science” The new antibody, TYHF-1, specifically targets certain hair-related structures.
New steroid derivatives show promise as anticancer agents, even against resistant cells.
11 citations
,
August 2010 in “Developmental neurobiology” Ptprq has multiple forms that change during inner ear development.
12 citations
,
September 2015 in “Drug Design Development and Therapy” AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
January 2006 in “Durham e-Theses (Durham University)” Id proteins, especially Id2 and Id3, are crucial for hair follicle development and stem cell regulation.
43 citations
,
March 1942 in “The Journal of experimental medicine/The journal of experimental medicine” Mice need pantothenic acid to make inositol.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.